Trust Investment Advisors Decreases Holdings in Pfizer Inc. (NYSE:PFE)

Trust Investment Advisors trimmed its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 59.1% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 18,278 shares of the biopharmaceutical company's stock after selling 26,439 shares during the period. Trust Investment Advisors' holdings in Pfizer were worth $485,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the stock. Charles Schwab Investment Management Inc. lifted its position in shares of Pfizer by 19.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company's stock valued at $4,124,330,000 after buying an additional 25,315,159 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Pfizer during the 4th quarter worth approximately $274,694,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Pfizer by 22.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 38,068,879 shares of the biopharmaceutical company's stock valued at $1,101,713,000 after acquiring an additional 6,977,587 shares during the last quarter. Fisher Asset Management LLC boosted its stake in Pfizer by 79.5% in the fourth quarter. Fisher Asset Management LLC now owns 11,148,116 shares of the biopharmaceutical company's stock valued at $295,760,000 after acquiring an additional 4,938,209 shares in the last quarter. Finally, Van ECK Associates Corp grew its holdings in Pfizer by 28.5% in the fourth quarter. Van ECK Associates Corp now owns 21,286,805 shares of the biopharmaceutical company's stock worth $564,739,000 after purchasing an additional 4,726,549 shares during the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

PFE has been the subject of a number of recent analyst reports. Truist Financial lowered their price objective on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research report on Wednesday, December 18th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a research note on Monday, March 10th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 8th. Finally, Citigroup decreased their price target on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Pfizer has an average rating of "Moderate Buy" and an average target price of $31.92.

Insider Transactions at Pfizer

In other Pfizer news, Director Ronald E. Blaylock purchased 19,457 shares of Pfizer stock in a transaction that occurred on Thursday, February 13th. The stock was bought at an average price of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now owns 27,707 shares of the company's stock, valued at $710,684.55. This trade represents a 235.84 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 0.06% of the company's stock.

Pfizer Stock Performance

Shares of PFE traded up $0.06 during mid-day trading on Friday, reaching $25.07. The company had a trading volume of 18,191,236 shares, compared to its average volume of 44,924,969. The stock has a market capitalization of $142.19 billion, a P/E ratio of 17.77, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The stock has a 50 day moving average of $26.09 and a two-hundred day moving average of $26.97. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion for the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter last year, the company earned $0.10 EPS. The business's revenue was up 24.7% on a year-over-year basis. On average, analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.